This morning, drug maker Sanofi (makers of the controversial drug heart drug Multaq) has posted its financial information for the third quarter. The company is showing that its net profit has dropped 3 percent to 2.40 billion euros, even though sales were up 5 percent to 8.75 billion euros.
Patent expiries on various drugs are not helping matters. Revenues from the company’s Taxotere (docetaxel) slumped 64.8 percent to 186 million euros, while the Ambien (zolpidem) sleep franchise sank 43.6 percent to 121 million euros. However, some drugs are showing an increase in profits. One of those drugs in the new anti-arrhythmic Multaq, which has made 66 million euros despite the drug’s increased risks of patients suffering from liver failure and the halted PALLAS study that was causing patients to suffer from worsening heart complications while on the drug.
The PALLAS study was halted after participants started dying while taking Multaq as part of their treatment for permanent atrial fibrillation (AF). Originally, Multaq was approved to treat temporary AF. Now that the drug has been found to make AF worse for some patients, many doctors have been advised to stop prescribing Multaq to patients unless nothing else is working.
For its part, the FDA has been reviewing Multaq, and other AF treatments are being approved in the hopes of finding one that will be less dangerous to patients’ health. Some doctors are refusing to use Multaq at all from fear of the dangers involved. Yet with all of these warnings and dangers, the drug still managed to bring in a hefty profit for Sanofi.
If you or a loved one have suffered from ill effects after taking Multaq, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.
About Greg Jones Law
You May Also Like